John Thornback
Chairman at Centre For Probe Development & Commercialization
Profile
John Thornback is currently the Chairman at Centre For Probe Development & Commercialization.
He previously worked as the Chief Executive Officer at Enigma Diagnostics Ltd., Chief Executive Officer & General Manager at Resolution Pharmaceuticals, Inc., Chief Executive Officer at Dx assays Pte Ltd., Director-Research & Development at Medgenix Diagnostics SA, Managing Director at Hammersmith Imanet Ltd., Managing Director at A.A.
Hammersmith Insurance, Inc., and Managing Director at Apta Biosciences Ltd.
He also worked as a Lecturer at Loughborough University and Chelsea College.
He is a Professor at Specialist Diabetes Research & Treatment Centre LLC.
Dr. Thornback completed his undergraduate and doctorate degrees from Imperial College London.
John Thornback active positions
Companies | Position | Start |
---|---|---|
Centre For Probe Development & Commercialization
Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Chairman | - |
Former positions of John Thornback
Companies | Position | End |
---|---|---|
Loughborough University | Corporate Officer/Principal | 31/12/1987 |
Apta Biosciences Ltd.
Apta Biosciences Ltd. Medical SpecialtiesHealth Technology Apta Biosciences Ltd. develops and commercializes synthetic antibody alternatives. It is a synthetic biology company specialized in developing unique, proprietary molecules that can be used broadly across diagnostics and therapeutics to facilitate and expand scientific discovery enabling the development of new healthcare solutions. The company was founded by Fredrik Edenius, William Addison and Shozo Fujita in 2013 and is headquartered in London, the United Kingdom. | Chief Executive Officer | - |
Dx assays Pte Ltd.
Dx assays Pte Ltd. Medical SpecialtiesHealth Technology Established in 2008, Dx assays is Singapore's first commercial developer of molecular assays. Their company specializes in Nucleic Acid-based Test (NAT) development. They offer highly customizable services in assay design, development and validation for client-provided content in areas such as infectious disease testing, assay integration and development of companion diagnostic assays. Its laboratories are equipped with the state-of-the-art technologies and are operated by highly qualified personnel under the compliance of ISO-13485 : 2003. | Chief Executive Officer | - |
Specialist Diabetes Research & Treatment Centre LLC
Specialist Diabetes Research & Treatment Centre LLC Medical/Nursing ServicesHealth Services Specialist Diabetes Research & Treatment Centre LLC specializes in diabetes treatment, research, training and public health awareness. Its services include diabetes, endocrinology, bariatric & metabolic, antenatal, cardiology, nephrology, podiatry, ophthalmology, radiology, dietetic services, laboratory, and pharmacy. The company was founded in May 2006 and is headquartered Abu Dhabi, United Arab Emirates. | Corporate Officer/Principal | - |
Chelsea College | Corporate Officer/Principal | - |
Training of John Thornback
Imperial College London | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 11 |
---|---|
Myconostica Ltd.
Myconostica Ltd. Electronic Equipment/InstrumentsElectronic Technology Myconostica Ltd. developed molecular diagnostic fungal testing kits. The company was founded in February 2006 and is headquartered in Cambridge, the United Kingdom. | Electronic Technology |
Resolution Pharmaceuticals, Inc. | |
Hammersmith Imanet Ltd. | |
Enigma Diagnostics Ltd.
Enigma Diagnostics Ltd. Medical SpecialtiesHealth Technology Enigma Diagnostics Ltd. develops next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings. It offers Enigma Instruments, Enigma MiniLab, and Enigma technology and IP. The firm has operation in Salisbury and San Diego. The company was founded in 2004 and is headquartered in Salisbury, the United Kingdom. | Health Technology |
Aerelink Ltd.
Aerelink Ltd. Wireless TelecommunicationsCommunications Aerelink Ltd. provides wireless networking services. The private company is based in Widnes, UK. and has subsidiaries in United Kingdom. | Communications |
Medgenix Diagnostics SA
Medgenix Diagnostics SA Medical SpecialtiesHealth Technology Part of Thermo Fisher Scientific, Inc., Medgenix Diagnostics SA is a Belgian company that specializes in making radioimmunology assays for in-vitro use. Medgenix Diagnostics was acquired by Biosource International, Inc. from MDS Nordion, Inc. on June 05, 1996 for $6.87 million. | Health Technology |
A.A. Hammersmith Insurance, Inc. | |
Specialist Diabetes Research & Treatment Centre LLC
Specialist Diabetes Research & Treatment Centre LLC Medical/Nursing ServicesHealth Services Specialist Diabetes Research & Treatment Centre LLC specializes in diabetes treatment, research, training and public health awareness. Its services include diabetes, endocrinology, bariatric & metabolic, antenatal, cardiology, nephrology, podiatry, ophthalmology, radiology, dietetic services, laboratory, and pharmacy. The company was founded in May 2006 and is headquartered Abu Dhabi, United Arab Emirates. | Health Services |
Dx assays Pte Ltd.
Dx assays Pte Ltd. Medical SpecialtiesHealth Technology Established in 2008, Dx assays is Singapore's first commercial developer of molecular assays. Their company specializes in Nucleic Acid-based Test (NAT) development. They offer highly customizable services in assay design, development and validation for client-provided content in areas such as infectious disease testing, assay integration and development of companion diagnostic assays. Its laboratories are equipped with the state-of-the-art technologies and are operated by highly qualified personnel under the compliance of ISO-13485 : 2003. | Health Technology |
Apta Biosciences Ltd.
Apta Biosciences Ltd. Medical SpecialtiesHealth Technology Apta Biosciences Ltd. develops and commercializes synthetic antibody alternatives. It is a synthetic biology company specialized in developing unique, proprietary molecules that can be used broadly across diagnostics and therapeutics to facilitate and expand scientific discovery enabling the development of new healthcare solutions. The company was founded by Fredrik Edenius, William Addison and Shozo Fujita in 2013 and is headquartered in London, the United Kingdom. | Health Technology |
Centre For Probe Development & Commercialization
Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Health Technology |
- Stock Market
- Insiders
- John Thornback